This invention describes a method to treat and reduce the risk for acute lung injury (ALI) associated with radiation, infection, trauma, and another environmental-related lung injury. The method described involves the administration of analogs or derivatives of Sphingosine 1 Phosphate (S1P) receptor agonists that have similar properties to S1P that similarly reduce infection and radiation-associated ALI.
Acute lung injury (ALI) is a dangerous lung inflammation that develops in response to pulmonary and generalized acute diseases. It is commonly associated with sepsis, an infection that may lead to vascular leakage. The incidence of ALI in the United States is estimated to be around 200,000 with a mortality rate of 40%.
Current treatments for ALI do not have long-term efficacy and in many cases involve invasive machines, such as CPAP machines. This technology is a novel pharmaceutical method of treating and preventing ALI by enhancing the endothelial cell barrier, limiting the prevalence of vascular leakage as a result of sepsis. This in turn can limit the occurrence of ALI.
- Enhance endothelial cell barrier
- Prevent vascular leakage
- Treat and prevent acute lung injury
- Preventative measure against ALI
- Limits the occurrence of sepsis
- Less-invasive than current treatment options
- Higher efficacy than current treatments
TTO Home Page: https://arizona.technologypublisher.com
Name: Mitch Graffeo
Title: Sr. Licensing Manager - COM-T